• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    BioMarin to Present at the TD Cowen 45th Annual Healthcare Conference on Tuesday, March 4 at 6:50 AM PT / 9:50 AM ET in Boston, MA

    2/25/25 9:00:00 AM ET
    $BMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BMRN alert in real time by email

    SAN RAFAEL, Calif., Feb. 25, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that management will present at the TD Cowen 45th Annual Healthcare Conference on Tuesday, March 4, 2025, at 6:50 AM PT / 9:50 AM ET in Boston, MA.

    BioMarin Pharmaceutical logo (PRNewsfoto/BioMarin Pharmaceutical Inc.)

    An audio webcast of the presentation will be available live. You can access the webcast at: https://investors.biomarin.com/. An archived version of the remarks will also be available through the Company's website for a limited time following the conference. 

    About BioMarin

    BioMarin is a global biotechnology company dedicated to translating the promise of genetic discovery into medicines that make a profound impact on the life of each patient. The San Rafael, California-based company, founded in 1997, has a proven track record of innovation with eight commercial therapies and a strong clinical and preclinical pipeline. Using a distinctive approach to drug discovery and development, BioMarin pursues treatments that offer new possibilities for patients and families around the world navigating rare or difficult-to-treat genetic conditions. To learn more, please visit www.biomarin.com. 

    Contacts:



    Investors

    Media

    Traci McCarty

    Marni Kottle

    BioMarin Pharmaceutical Inc.

    BioMarin Pharmaceutical Inc.

    (415) 455-7558 

    (650) 374-2803

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/biomarin-to-present-at-the-td-cowen-45th-annual-healthcare-conference-on-tuesday-march-4-at-650-am-pt--950-am-et-in-boston-ma-302383918.html

    SOURCE BioMarin Pharmaceutical Inc.

    Get the next $BMRN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BMRN

    DatePrice TargetRatingAnalyst
    2/24/2025$98.00Perform → Outperform
    Oppenheimer
    11/15/2024$95.00Outperform
    Wolfe Research
    10/30/2024Outperform → Mkt Perform
    William Blair
    10/10/2024$79.00Outperform
    Raymond James
    8/20/2024$94.00 → $110.00Mkt Perform → Outperform
    Bernstein
    5/17/2024$104.00 → $72.00Outperform → Neutral
    Robert W. Baird
    5/14/2024$113.00Outperform
    Evercore ISI
    11/15/2023$100.00Overweight
    Wells Fargo
    More analyst ratings